SIGNAL // LOADING
Loading page
Glossary term
Wegovy
Also known as Semaglutide (chronic weight management indication)
Brand-name semaglutide. FDA-approved for chronic weight management in adults at BMI 30+, or 27+ with a comorbidity.
Wegovy is Novo Nordisk's semaglutide formulation labeled for chronic weight management in adults with BMI 30+ or 27+ with comorbidity. STEP-1 showed ~14.9% mean weight loss at 68 weeks on 2.4 mg weekly. Wegovy and Ozempic contain the same molecule with different indications, labels, and supply dynamics. Eligibility review covers thyroid history, pancreatitis, pregnancy, and interaction with current medications.
Medically reviewed byDr. Lena Okafor, MD
Medical Director - updated April 2026How we review
External references
Related
Connected context
Related terms
Related guides
GLP-1 eligibility explained: who qualifies, who doesn't, and whyTirzepatide vs semaglutide: how to think about the choiceWhat a comprehensive metabolic panel actually tells youProvider-reviewed care vs DIY supplementation: when each makes sensePCOS labs: the markers that actually drive the planGLP-1 side effects: what's normal, what needs review, what stops the protocolHolding the loss after GLP-1: protein, training, and the maintenance planFasting insulin and HOMA-IR: the metabolic signal that precedes A1c by yearsCreatine, protein, and the two supplements that actually moved your labsWeight-loss plateaus on GLP-1: what to change first